Target intelligence / Profile preview

Monocarboxylate transporter 12 (SLC16A12)

Target
SLC16A12
Molecular classification
Transporter, Solute carrier family, Monocarboxylate transporter
01

Overview

Monocarboxylate transporter 12 (SLC16A12) is a multi-pass transmembrane protein of the solute carrier 16 (SLC16) family, containing 12 transmembrane helices, which mediates the facilitated diffusion of creatine and guanidinoacetate across cellular membranes, independent of sodium, chloride, or pH gradients[1][5][10]. It is highly expressed in tissues including the kidney and ocular lens, where it plays a critical role in creatine homeostasis and energy metabolism[5][12][15]. Loss-of-function mutations in SLC16A12 are associated with a syndromic presentation comprising juvenile cataracts, microcornea, and renal glucosuria, while recent evidence implicates impaired creatine or guanidinoacetate transport as a mechanism underlying disease pathology[5][7][13]. Though most disease associations are monogenic and rare, broader implications in cancer or common metabolic diseases are considered for SLC16 family members but not yet established for SLC16A12[3][4][11].

Other names
Monocarboxylate transporter 12MCT12Creatine transporter 2CRT2Solute carrier family 16 member 12monocarboxylic acid transporter 12CJMGCTRCT47
02

Biological functions

Creatine transportMonocarboxylic acid transportCellular energy metabolismHomeostasis (lens, kidney)Export of guanidinoacetate
03

Disease associations

Cataract (juvenile cataract-microcornea-glucosuria syndrome)Renal glucosuriaPotential role in age-related cataractPossible, but not established, role in cancer (general SLC16A family association)
04

Safety considerations

Reduced creatine or guanidinoacetate transport may cause metabolic dysfunction in tissues such as kidney and lensMutations can cause developmental or degenerative eye and kidney diseases
05

Biomarkers

Cataract 47 (monogenic disease with SLC16A12 mutation)Juvenile cataract-microcornea-renal glucosuria syndromePotential, but not established, use as a biomarker for renal or ocular disease

Beyond the preview

Go deeper on Monocarboxylate transporter 12 (SLC16A12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monocarboxylate transporter 12 (SLC16A12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call